Dihydrofolate reductase inhibitors: new developments in antiparasitic chemotherapy

Bibliography

• FERONE R: Folate metabolism in malaria. Bull. WHO (1977) 55(2): 291–298.
   PubMedGoogle Scholar
• GORLICK R, GOKER E, TRIPPETT T et Med. (1996) 335(14):1041–1048.
   Google Scholar
• MOSCOW JA: Methotrexate transport and resistance. Leuk. Lymphoma (1998) 30(3-4):215–224.
   PubMedGoogle Scholar
• PAYNE D: Spread of chloroquine resistance
   Google Scholar
• DURAND R, DI PIAZZA JP, LONGUET C et al.: Increased incidence of cycloguanil resistance in malaria cases entering France
   Google Scholar
• CANFIELD CJ, MILHOUS WK, AGER AL et al: P5-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am. j Trop. Med. Hyg. (1993)
   Google Scholar
• KINYANJUI SM, MBERU EK, WINSTANLEY PA, JACOBUS DP, WATKIN WM: The antimalarial triazine WR99210 and the prodrug P5-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am. j Trop. Med. Hyg. (1999) 60(6):943–947.
   PubMedGoogle Scholar
• •A paper on original drugs by a leading team in the field.
   Google Scholar
• WOODEN JM, HARTWELL LH, VASQUEZ B, SIBLEY CH: Analysis in yeast of antimalarial drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mal Biochem. Parasitol (1997) 85(0:25–40.
   PubMedGoogle Scholar
• SCOTT HV, RIECKMANN KH, O'SULLIVAN WJ: Synergistic antimalarial activity of dapsone/dihydrofolate reductase inhibitors and the interaction of antifol, antipyrimidine and antipurine combinations against Plasmodium falciparum in vitro. Trans. R. Soc. Trop. Med. Hyg. (1987) 81(5):715–721.
   PubMedGoogle Scholar
• WINSTANLEY PA, MBERU EK, SZWANDT IS, BRECKENRIDGE AM, WATKINS WM: In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocytes CFUs. Antimicrob. Agents Chemother. (1995) 39(4):948–952.
   PubMedGoogle Scholar
• AMUKOYE E, WINSTANLEY PA, WATKINS WM et al: Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob. Agents Chemother. (1997) 41(10):2261–2264.
   PubMedGoogle Scholar
• LOOAREESUWAN S, CHULAY JD, CANFIELD CJ, HUTCHINSON DB: Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am. Trop. Med. Hyg. (1999) 60(4):533–541.
   PubMed Web of Science ®Google Scholar
• QUEENER SF: New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii J. Med. Chem. (1995) 38(24):4739–4759.
   Google Scholar
• •An interesting paper in the field of Pneumocystis
   Google Scholar
• BARLETT MS, SHAW M, NAVARAN P, SMITH JW, QUEENER SF: Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob. Agents Chemother. (1995) 39(11):2436–2441.
   PubMedGoogle Scholar
• ROSOWSKY A, PAP OULIS AT, FORSCH RA, QUEENER SF: Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim. j Med. Chem. (1999) 42(6):1007–1017.
   PubMedGoogle Scholar
• •A major paper about promising drugs.
   Google Scholar
• GANGJEE A, ZHU Y, QUEENER SF: 6-Substituted 2,4- diaminopyrido [32d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocysis and iand as antitumor agents. j Med. Chem. (1998) 41(23):4533–4541.
   PubMed Web of Science ®Google Scholar
• GANGJEE A, ADAIR O, QUEENER SF: Pneumocystis carinll and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methy1-6-Rmonosubstitutedanilino)methyl]pyrido [2, 3-d]pyrimidines. j Med. Chem. (1999) 42(13):2447–2455.
   PubMed Web of Science ®Google Scholar
• ROSOWSKY A, QUEENER SF, CODY V: Inhibition of dihydrofolate reductases from Toxoplasma goncili, Pneumocystis canna and rat liver by rotationally restricted analogues of pyrimethamine and metoprine. Drug. Des. Discov. (1999) 16(1):25–40.
   PubMedGoogle Scholar
• MCKIE JH, DOUGLAS KT, CHAN C et al.: Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. Med. Chem. (1998) 41(9):1367–1370.
   Google Scholar
• KUYPER LF, BACCANARI DP, JONES MLET et al.: High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialky1-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. J. Med. Chem. (1996), 39(4):892–903.
   PubMedGoogle Scholar
• STEVENS MFG, PHILLIP KS, RATHBONE DL et al: Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis cannii dihydrofolate reductase. Med. Chem. (1997) 40(12):1886–1893.
   Google Scholar
• ROBSON C, MEEK MA, GREUNWALDT JD etal.: Nonclassical 2,4-diamino-5-ary1-6-ethylpyrimidine antifolates: Activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. I Med. Chem. (1997) 40(19):3040–3048.
   Google Scholar
• CHOWDHURY SF, VILLAMOR VB, GUERRERO RH et al: Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase. J. Med. Chem. (1999) 42(20:4300–4312
   PubMedGoogle Scholar
• BRUN-PASCAUD M, CHAU F, GARRY L et al: Combination of P5-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis cannii dual infection in a rat model. Antimicrob. Agents Chemother. (1996) 40(9):2067–2070.
   PubMedGoogle Scholar
• MARTINEZ A, ALLEGRA CJ, KOVACS JA: Efficacy of epiroprim (Ro 11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Am. J Trop. Med. Hyg. (1996) 54(3):249–252.
   PubMedGoogle Scholar
• CHANG HR, ARSENIJEVIC D, COMTE R et al: Activity of Epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma Antimicrob. Agents Chemother. (1994) 38(8):1803–1807.
   PubMedGoogle Scholar
• DUBEY JP, LINDSAY DS: Neosporosis. Parasitol Today (1993) 9(12):452–458.
   PubMedGoogle Scholar
• LINDSAY DS, BUTLER JM, RIPPEY NS, BLAGBURN BL: Demonstration of synergistic effects of sulfonamides and dihydrofolate reductaseithymidylate 1289 Expert Op/n. Ther. Patents (2001)11(8) synthase inhibitors against Neospora canna tachyzoites in cultured cells, and characterization of mutants resistant to pyrimethamine. Am. j Vet. Res. (1996) 57(1):68–72.
   Google Scholar
• CAZZULO JJ, STOKA V, TURK V: Cruzipain, the major cysteine proteinase from the protozoan parasite Tryparrosoma cruzi. Biol. Chem. (1997) 378(1):1–10.
   PubMedGoogle Scholar
• MCKERROW JH, ENGEL JC, CAFFREY CR: Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. (1999) 7(4):639–644.
   PubMedGoogle Scholar
• MCKERROW JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Intl Parasitol (1999) 29(6):833–837.
   PubMedGoogle Scholar
• COOMBS GH, MOTTRAM JC: Parasite proteinases and amino acid metabolism: possibilities for chemotherapeutic exploitation. Parasitology (1997) 114:S61–80.
   Google Scholar
• ROSENTHAL PJ: Proteases of malaria parasites: new targets for chemotherapy. Emerg. Infect. Dis. (1998) 4(1):49–57.
   PubMed Web of Science ®Google Scholar
• GRAY N, D'ETIVAUD L, DOERIG C, MEIJER L: ATP-site directed inhibitors of cyclin-dependent kinases. Cun: Med. Chem. (1999) 6(9):859–875.
   PubMedGoogle Scholar
• MEIJER L, LECLERC S, LEOST M: Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. (1999) 82(2-3):279–284.
   PubMedGoogle Scholar
• INGRAM GM, KINNAIRD JH: Ribonucleotide reductase: a new target for antiparasitic therapies. Parasitol. Today (1999) 15(8):338–342.
   PubMedGoogle Scholar
• URBINA JA: Lipid biosynthesis pathwaysas chemotherapeutic targets in kinetoplastid parasites. Parasitology (1997) 114:S91–99.
   PubMed Web of Science ®Google Scholar
• DAVIDSON RN, DI MARTINO L, GRAD ONI L et al: Short-course treatment of visceral leishmaniasis with liposomal amphotericin B. Clin Infect. Dis. (1996) 22(6):938–943.
   PubMed Web of Science ®Google Scholar
• COWMAN AF, MORRY MJ, BIGGS BA, CROSS GA, FOOTE SJ: Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA (1988) 85(23):9109–9113.
   PubMed Web of Science ®Google Scholar
• PETERSON DS, WALLIKER D, WELLEMS TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA (1988) 85(23):9114–9118.
   PubMed Web of Science ®Google Scholar
• HYDE JE: The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol Ther. (1990) 48(1):45–59.
   PubMedGoogle Scholar
• PETERSON DS, MILHOUS WK, WELLEMS TE: Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA (1990) 87(8):3018–3022.
   PubMedGoogle Scholar
• BASCO LK, DE PECOULAS PE, WILSON CM, LE BRAS J, MAZABRAUD A: Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol. Biochem. Parasitol (1995) 69(1):135–138
   PubMedGoogle Scholar
• WHITE NJ: Preventing antimalarial drug resistance through combinations. Dug Resist. Updates (1998) 1:3–9.
   PubMed Web of Science ®Google Scholar